AR044949A1 - MUTANTS OF IFNAR2, ITS PRODUCTION AND USE - Google Patents
MUTANTS OF IFNAR2, ITS PRODUCTION AND USEInfo
- Publication number
- AR044949A1 AR044949A1 ARP040102282A AR044949A1 AR 044949 A1 AR044949 A1 AR 044949A1 AR P040102282 A ARP040102282 A AR P040102282A AR 044949 A1 AR044949 A1 AR 044949A1
- Authority
- AR
- Argentina
- Prior art keywords
- ifnar2
- polypeptide
- ifn
- medicament
- beta
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un polipéptido mutante del IFNAR2 (MIFNAR2) mutado en residuos de aminoácidos histidina 78 y asparagina 100, que posee mayor afinidad para el interferón-beta (INF-beta) que el polipéptido de tipo silvestre, o un análogo, derivado funcional, proteína de fusión o sal del mismo. Reivindicación 16: Un ADN que codifica un polipéptido de acuerdo con cualquiera de las reivindicaciones 1-14. Reivindicación 25: El uso del mutante el IFNAR2 de acuerdo con cualquiera de las reivindicaciones 1 a 15 en la fabricación de un medicamento. Reivindicación 26: El uso de acuerdo con la reivindicación 25, donde el medicamento también comprende el IFN. Reivindicación 29: El uso de acuerdo con cualquiera de las reivindicaciones 25 a 28, para modular los efectos del IFN.An IFNAR2 mutant polypeptide (MIFNAR2) mutated in amino acid residues histidine 78 and asparagine 100, which has a greater affinity for interferon-beta (INF-beta) than the wild-type polypeptide, or an analogue, functional derivative, fusion protein or get out of it. Claim 16: A DNA encoding a polypeptide according to any one of claims 1-14. Claim 25: Use of the IFNAR2 mutant according to any one of claims 1 to 15 in the manufacture of a medicament. Claim 26: The use according to claim 25, wherein the medicament also comprises the IFN. Claim 29: Use according to any of claims 25 to 28, to modulate the effects of IFN.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP040102282 AR044949A1 (en) | 2004-06-29 | 2004-06-29 | MUTANTS OF IFNAR2, ITS PRODUCTION AND USE |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP040102282 AR044949A1 (en) | 2004-06-29 | 2004-06-29 | MUTANTS OF IFNAR2, ITS PRODUCTION AND USE |
Publications (1)
Publication Number | Publication Date |
---|---|
AR044949A1 true AR044949A1 (en) | 2005-10-12 |
Family
ID=42778309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102282 AR044949A1 (en) | 2004-06-29 | 2004-06-29 | MUTANTS OF IFNAR2, ITS PRODUCTION AND USE |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR044949A1 (en) |
-
2004
- 2004-06-29 AR ARP040102282 patent/AR044949A1/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP024346A (en) | PEPTIDES THAT ACT AS GLON-RECEPTOR AGONISTS AND AS GLUCAGON RECEPTOR ANTAGONISTS AND THEIR METHODS OF PHARMACOLOGICAL USE | |
ATE466085T1 (en) | PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES | |
LU91680I2 (en) | "rilonacept and its pharmaceutically acceptable derivatives (ARCALYSR)" | |
DE602006020123D1 (en) | GLUCAGON LIKE PEPTIDE-2 (GLP-2) ANALOG | |
BRPI0512286A (en) | angiogenesis inhibiting chimeric proteins and the use | |
CR20110245A (en) | MUTANTS FGF21 AND USE OF THE SAME. | |
ATE544461T1 (en) | RECONSTITUTED SURFACTANTS WITH IMPROVED PROPERTIES | |
ES8608043A1 (en) | Pharmaceutical and veterinary preparations of cystein-125-depleted muteins of Interleukin-2 and their production. | |
DK1132403T3 (en) | TGF G Beta1 Inhibitor Peptides | |
DE60125381D1 (en) | COMPOSITIONS AND METHODS FOR ANALOGUE OF G-CSF | |
ATE388165T1 (en) | HUMAN CNP GENE AND PRECUSSION PROTEIN | |
ATE490323T1 (en) | ADIPONECTIN RECEPTOR AND GENE CODING IT | |
BRPI0207933B8 (en) | Mutant interleukin-18 polypeptide and pharmaceutical composition | |
TW200641126A (en) | N protein mutants of porcine reproductive and respiratory syndrome virus | |
BR0312521A (en) | Methods for the separation and purification of fibrinogen and at least one other protein and for the co-purification of fibrinogen and factor xiii, use of immobilized metal ion affinity chromatography, fibrinogen, pharmaceutical kit, and pharmaceutical formulations and freeze-dried fibrinogen | |
ATE417618T1 (en) | HIGH EXPRESSION LEVEL FACTOR VIII POLYPEPTIDES CODING NUCLEIC ACID AND AMINO ACID SEQUENCES AND METHODS OF USE | |
MX9300741A (en) | PARTICLES OF HARD MATERIAL, BASED ON OXIDES AND PROCEDURE FOR ITS OBTAINING. | |
ATE520776T1 (en) | RECOMBINANT HERPES VIRUS AND USE THEREOF | |
DE69435177D1 (en) | Chemoattraction triggering factor from lymphocytes and its use | |
DK1373502T3 (en) | Dopaminergic neuronal survival promoting factors and their causes | |
ES2169384T3 (en) | CHROMATOGRAPHIC PROCEDURE FOR OBTAINING HIGHLY PURIFIED CYCLOSPORIN AND ANALOG CYCLOSPORINS. | |
AR044949A1 (en) | MUTANTS OF IFNAR2, ITS PRODUCTION AND USE | |
MY197491A (en) | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof | |
RS52448B (en) | Antitumoral pharmaceutical composition containing polypeptide fragments of serralyysins | |
DK1478659T3 (en) | Biologically active peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |